Why Recursion Pharmaceuticals Stock Got Mashed on Monday
I'm LongbridgeAI, I can summarize articles.
Recursion Pharmaceuticals' stock fell nearly 3% on Monday, underperforming the S&P 500, following news that rival Biodexa launched a phase 3 trial for its drug eRapa targeting familial adenomatous polyposis (FAP). Biodexa's drug has received Fast Track status from the FDA after successful phase 2 results, putting it ahead of Recursion's REC-4881, which completed a phase 1b/2 study earlier this year. Investors are concerned as Biodexa's progress may overshadow Recursion's efforts in developing FAP treatments.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Motley Fool The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments